What is NeoGenomics' operating income?

NeoGenomics' total operating income in 2025 was -$115.88 million, based on the following breakdown: Total Gross Profit: $314.29 million Total Operating Expenses: $430.17 million

NeoGenomics (NEO) Financials

$13.40 +0.26 (+1.98%)

Closing price 07/28/2026 04:00 PM Eastern

Extended Trading

$13.86 +0.46 (+3.40%)

As of 07/28/2026 04:56 PM Eastern

Compare

Annual Income Statements for NeoGenomics

This table shows NeoGenomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-2.66	-31	-11	6.09	8.01	4.17	-8.35	-144	-88	-79	-108
Consolidated Net Income / (Loss)	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79	-108
Net Income / (Loss) Continuing Operations	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79	-108
Total Pre-Tax Income	-4.49	-7.84	-2.65	3.82	3.65	-14	-15	-159	-97	-81	-110
Total Operating Income	-5.64	2.16	2.90	10	13	-14	-119	-158	-108	-92	-116
Total Gross Profit	44	98	102	127	197	186	187	188	245	290	314
Total Revenue	100	232	240	277	409	444	484	510	592	661	727
Operating Revenue	100	232	240	277	409	444	484	510	592	661	727
Total Cost of Revenue	56	134	138	149	212	259	297	322	347	370	413
Operating Cost of Revenue	56	134	138	149	212	259	297	322	347	370	413
Total Operating Expenses	49	96	99	117	184	200	306	346	352	382	430
Selling, General & Admin Expense	34	64	70	85	128	144	221	243	243	260	273
Marketing Expense	12	24	24	29	47	48	63	67	71	85	92
Research & Development Expense	4.20	4.65	3.64	3.00	8.49	8.23	22	30	27	31	37
Impairment Charge	0.00	3.46	-	-	-	-	-	-	0.00	0.00	28
Restructuring Charge	-	-	-	-	-	0.00	0.00	4.52	11	6.66	0.00
Total Other Income / (Expense), net	1.15	-10.00	-5.55	-6.22	-9.36	-0.06	104	-1.72	11	11	5.61
Interest Expense	0.85	10.00	5.54	6.23	4.73	12	8.22	7.58	6.91	6.62	3.75
Interest & Investment Income	-	-	-	-	-	-	3.14	6.08	17	18	9.07
Other Income / (Expense), net	2.00	0.00	-0.01	0.01	-4.63	12	109	-0.21	0.64	-0.38	0.30
Income Tax Expense	-1.95	-1.70	-2.25	1.18	-4.36	-18	-6.73	-15	-9.13	-1.95	-2.24
Basic Earnings per Share	($0.04)	($0.40)	($0.14)	$0.07	$0.08	-	-	($1.16)	($0.70)	($0.62)	($0.84)
Weighted Average Basic Shares Outstanding	60.53M	77.54M	79.43M	85.62M	100.47M	108.58M	119.96M	124.22M	125.50M	126.66M	128.10M
Diluted Earnings per Share	($0.04)	($0.40)	($0.14)	$0.07	$0.08	-	-	($1.16)	($0.70)	($0.62)	($0.84)
Weighted Average Diluted Shares Outstanding	60.53M	77.54M	79.43M	91.57M	103.62M	111.79M	119.96M	124.22M	125.50M	126.66M	128.10M
Weighted Average Basic & Diluted Shares Outstanding	66.40M	78.82M	80.51M	94.57M	104.83M	116.94M	124.03M	127.46M	127.61M	128.46M	129.81M

This table shows NeoGenomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17	2.24
Consolidated Net Income / (Loss)	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17	2.24
Net Income / (Loss) Continuing Operations	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17	2.24
Total Pre-Tax Income	-15	-28	-19	-18	-16	-26	-46	-26	-12	-18	1.83
Total Operating Income	-19	-31	-22	-21	-18	-28	-48	-27	-13	-18	-9.77
Total Gross Profit	68	65	72	75	77	73	77	80	83	81	92
Total Revenue	156	156	165	168	172	168	181	188	190	187	202
Operating Revenue	156	156	165	168	172	168	181	188	190	187	202
Total Cost of Revenue	88	91	92	93	95	95	104	107	107	106	110
Operating Cost of Revenue	88	91	92	93	95	95	104	107	107	106	110
Total Operating Expenses	86	96	94	96	96	101	125	107	97	99	102
Selling, General & Admin Expense	60	66	63	67	64	68	72	70	64	66	64
Marketing Expense	18	20	22	20	22	23	24	22	23	24	27
Research & Development Expense	7.13	7.62	7.89	7.68	7.97	10	9.02	8.69	9.18	9.53	11
Impairment Charge	-	-	0.00	0.00	-	-	20	7.09	-	-	0.00
Total Other Income / (Expense), net	3.29	2.89	2.92	3.35	2.27	2.17	1.81	0.63	1.01	0.66	12
Interest Expense	1.68	1.69	1.67	1.64	1.62	1.62	0.93	0.60	0.60	0.60	-10
Interest & Investment Income	4.85	4.83	4.59	4.67	4.33	3.72	2.26	1.56	1.52	1.27	1.21
Other Income / (Expense), net	0.12	-0.26	-0.00	0.32	-0.43	0.07	0.48	-0.34	0.08	-0.01	-0.02
Income Tax Expense	-0.96	-0.62	-0.38	-0.15	-0.80	0.27	-0.72	0.74	-2.53	-0.47	-0.41
Basic Earnings per Share	-	($0.21)	-	($0.14)	-	($0.20)	($0.35)	($0.21)	-	($0.13)	$0.02
Weighted Average Basic Shares Outstanding	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.42M	128.10M	129.17M	129.63M
Diluted Earnings per Share	-	($0.21)	-	($0.14)	-	($0.20)	($0.35)	($0.21)	-	($0.13)	$0.02
Weighted Average Diluted Shares Outstanding	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.42M	128.10M	129.17M	130.83M
Weighted Average Basic & Diluted Shares Outstanding	127.61M	127.71M	128.16M	128.36M	128.46M	128.69M	129.18M	129.39M	129.81M	130.21M	128.48M

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-10	-11	0.30	-3.01	163	78	66	-54	79	25	-207
Net Cash From Operating Activities	6.39	21	18	45	23	1.46	-27	-66	-1.95	7.02	5.23
Net Cash From Continuing Operating Activities	6.39	21	18	45	23	1.46	-27	-66	-1.95	7.02	5.23
Net Income / (Loss) Continuing Operations	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79	-108
Consolidated Net Income / (Loss)	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79	-108
Depreciation Expense	6.73	16	16	16	20	26	30	35	37	39	36
Amortization Expense	0.41	11	7.44	6.47	10	14	26	37	38	36	34
Non-Cash Adjustments To Reconcile Net Income	3.73	10	7.75	7.36	17	-6.35	-84	36	28	37	74
Changes in Operating Assets and Liabilities, net	-1.95	-9.09	-12	13	-32	-37	10	-30	-18	-26	-30
Net Cash From Investing Activities	-75	-6.50	-14	-140	-20	-159	-632	0.52	77	13	-12
Net Cash From Continuing Investing Activities	-75	-6.50	-14	-140	-20	-159	-632	0.52	77	13	-12
Purchase of Property, Plant & Equipment	-2.22	-7.54	-14	-14	-20	-29	-64	-31	-29	-41	-27
Acquisitions	-73	1.04	0.00	-125	0.00	-37	-419	-	0.00	0.00	-6.45
Purchase of Investments	-	-	-	0.00	0.00	-99	-212	-98	-6.76	0.00	0.00
Sale and/or Maturity of Investments	-	-	-	0.00	0.00	5.36	63	117	112	54	20
Other Investing Activities, net	-	-	-	0.00	0.40	-	-	-	0.00	0.00	1.07
Net Cash From Financing Activities	58	-26	-4.10	92	159	236	725	12	4.55	4.65	-200
Net Cash From Continuing Financing Activities	58	-26	-4.10	92	159	236	725	12	4.55	4.65	-200
Repayment of Debt	-7.47	-62	-3.75	-40	-105	-98	-	-	0.00	0.00	-201
Issuance of Common Equity	0.94	3.77	2.59	9.02	11	20	15	13	4.62	4.65	0.96
Other Financing Activities, net	-	-	-5.42	-6.56	-7.20	-8.93	-32	-0.76	-0.07	0.00	0.00
Cash Interest Paid	0.91	5.42	5.16	6.51	4.78	2.93	3.07	3.40	3.38	3.83	1.69
Cash Income Taxes Paid	0.03	0.29	0.28	-0.03	0.32	0.25	0.15	0.18	0.18	0.21	0.52

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	36	-11	23	6.91	5.02	-21	-191	9.39	-4.50	-13	-21
Net Cash From Operating Activities	18	-26	14	9.25	9.80	-25	20	8.88	1.34	-8.14	20
Net Cash From Continuing Operating Activities	18	-26	14	9.25	9.80	-25	20	8.88	1.34	-8.14	14
Net Income / (Loss) Continuing Operations	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17	2.24
Consolidated Net Income / (Loss)	-14	-27	-19	-18	-15	-26	-45	-27	-9.88	-17	2.24
Depreciation Expense	9.58	9.91	9.75	9.62	9.83	9.37	9.14	8.80	8.76	8.78	8.58
Amortization Expense	9.51	9.09	9.09	9.09	9.09	8.36	8.62	8.02	8.02	7.63	2.69
Non-Cash Adjustments To Reconcile Net Income	1.70	8.89	13	6.48	8.53	12	35	19	8.20	10	-2.76
Changes in Operating Assets and Liabilities, net	11	-27	0.85	1.76	-2.32	-29	13	-0.07	-14	-18	3.18
Net Cash From Investing Activities	17	15	7.31	-3.52	-5.47	3.56	-9.31	-0.28	-6.31	-5.00	-8.32
Net Cash From Continuing Investing Activities	17	15	7.31	-3.52	-5.47	3.56	-9.31	-0.28	-6.31	-5.00	-8.32
Purchase of Property, Plant & Equipment	-7.06	-5.59	-13	-11	-12	-4.50	-6.32	-8.31	-7.87	-5.00	-8.22
Net Cash From Financing Activities	1.27	0.82	1.97	1.18	0.69	0.95	-202	0.77	0.43	-0.34	-12
Net Cash From Continuing Financing Activities	1.27	0.82	1.97	1.18	0.69	0.95	-202	0.77	0.43	-0.34	-12
Issuance of Common Equity	1.27	0.82	1.97	1.18	0.69	0.95	-1.18	0.77	0.43	-0.34	2.09
Cash Interest Paid	1.26	0.43	1.26	0.45	1.69	0.00	1.26	0.43	0.00	0.43	0.30
Cash Income Taxes Paid	-	0.09	0.09	0.14	-0.11	0.00	0.46	-	0.06	0.00	0.71

This table presents NeoGenomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	351	337	344	505	710	988	1,870	1,740	1,681	1,638	1,360
Total Current Assets	82	79	86	104	291	449	682	605	597	596	376
Cash & Equivalents	23	13	13	9.81	173	229	317	263	342	367	160
Accounts Receivable	49	56	60	77	94	107	112	120	131	151	159
Inventories, net	5.11	6.25	7.47	8.65	14	30	23	24	24	27	29
Prepaid Expenses	4.89	4.54	4.15	7.73	6.33	12	12	15	18	20	21
Other Current Assets	-	-	1.00	0.56	2.75	4.56	18	8.08	8.24	12	7.42
Plant, Property, & Equipment, net	35	34	37	61	64	86	109	102	92	94	85
Total Noncurrent Assets	234	224	222	340	355	454	1,079	1,032	992	948	899
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	-	-	-	-	0.05
Goodwill	146	147	147	198	199	211	527	523	523	523	524
Intangible Assets	88	77	74	140	127	121	442	408	373	340	287
Other Noncurrent Operating Assets	0.13	0.17	0.89	2.54	29	92	109	101	97	85	88
Total Liabilities & Shareholders' Equity	351	337	344	505	710	988	1,870	1,740	1,681	1,638	1,360
Total Liabilities	113	151	140	185	202	294	762	742	740	736	523
Total Current Liabilities	40	38	36	61	64	73	87	90	96	301	88
Accounts Payable	12	17	10	18	20	25	18	21	20	22	23
Accrued Expenses	7.37	4.25	6.14	8.99	7.55	12	18	15	15	13	12
Current Deferred Revenue	-	-	-	-	1.61	4.03	5.19	7.56	2.13	0.41	0.85
Current Employee Benefit Liabilities	6.22	8.35	9.48	19	21	25	38	40	53	62	48
Other Current Liabilities	-	-	1.41	7.23	8.81	7.81	8.02	6.65	5.61	3.38	4.80
Total Noncurrent Liabilities	73	112	103	124	138	221	674	652	643	434	435
Long-Term Debt	52	92	91	98	92	168	532	535	538	340	342
Noncurrent Deferred & Payable Income Tax Liabilities	16	15	6.69	22	16	5.42	55	35	24	22	18
Other Noncurrent Operating Liabilities	-	-	0.28	3.06	31	47	86	82	81	73	75
Commitments & Contingencies	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	210	164	172	320	507	694	1,108	998	942	902	837
Total Preferred & Common Equity	210	164	172	320	507	694	1,108	998	942	902	837
Total Common Equity	210	164	172	320	507	694	1,108	998	942	902	837
Common Stock	232	216	230	340	520	701	1,124	1,161	1,190	1,228	1,270
Retained Earnings	-22	-52	-58	-19	-11	-7.19	-15	-159	-247	-326	-434
Treasury Stock	-	-	-	-	-	-	-	-	-	-	0.00
Accumulated Other Comprehensive Income / (Loss)	-	0.00	0.27	-0.58	-1.62	0.01	-0.64	-3.90	-1.67	-0.21	0.00

This table presents NeoGenomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	1,709	1,695	1,678	1,640	1,643	1,641	1,601	1,394	1,375	1,347	1,352
Total Current Assets	585	585	587	574	584	590	574	393	382	374	381
Cash & Equivalents	276	289	306	332	355	362	346	155	164	146	146
Accounts Receivable	119	125	133	140	147	151	151	153	155	167	175
Inventories, net	24	25	24	20	23	24	30	34	28	30	27
Prepaid Expenses	16	17	19	19	17	18	23	23	22	24	24
Other Current Assets	7.62	8.43	9.32	9.31	9.16	8.31	12	19	13	6.61	9.81
Plant, Property, & Equipment, net	103	100	95	88	92	93	90	85	85	84	81
Total Noncurrent Assets	1,021	1,010	997	979	967	958	938	916	907	889	890
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	-	-	-	-	6.65
Goodwill	523	523	523	523	523	523	523	524	524	524	524
Intangible Assets	399	391	382	365	356	348	331	302	294	279	271
Other Noncurrent Operating Assets	99	97	92	91	88	87	84	90	88	86	88
Total Liabilities & Shareholders' Equity	1,709	1,695	1,678	1,640	1,643	1,641	1,601	1,394	1,375	1,347	1,352
Total Liabilities	735	739	731	717	727	733	713	540	536	518	567
Total Current Liabilities	87	95	93	77	290	296	280	100	98	85	106
Accounts Payable	23	18	17	18	17	17	16	27	23	26	21
Accrued Expenses	18	18	19	18	17	23	19	18	17	13	23
Current Deferred Revenue	6.07	5.71	3.62	1.14	0.97	0.59	1.16	1.08	1.58	0.56	0.19
Current Employee Benefit Liabilities	33	46	48	35	51	52	39	49	51	41	56
Other Current Liabilities	6.97	7.37	6.22	4.49	3.57	3.72	3.08	4.05	4.51	4.83	5.43
Total Noncurrent Liabilities	648	644	638	640	437	436	433	440	439	433	461
Long-Term Debt	536	537	537	539	340	340	341	341	341	342	374
Noncurrent Deferred & Payable Income Tax Liabilities	32	29	25	23	23	23	21	20	21	17	17
Other Noncurrent Operating Liabilities	80	79	75	78	75	74	72	79	76	73	70
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	974	956	947	923	916	908	888	854	838	829	786
Total Preferred & Common Equity	974	956	947	923	916	908	888	854	838	829	786
Total Common Equity	974	956	947	923	916	908	888	854	838	829	786
Common Stock	1,167	1,173	1,182	1,199	1,210	1,219	1,240	1,251	1,262	1,280	1,259
Retained Earnings	-190	-214	-233	-274	-293	-310	-352	-397	-424	-451	-449
Treasury Stock	-	-	-	-	-	-	-	-	-	-	-25
Accumulated Other Comprehensive Income / (Loss)	-2.83	-2.57	-1.85	-1.33	-1.02	-0.64	-0.06	0.03	0.07	0.00	0.00

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.62%	132.27%	3.64%	15.19%	47.73%	8.71%	8.97%	5.24%	16.07%	11.65%	10.11%
EBITDA Growth	-56.05%	722.95%	-10.19%	24.72%	20.75%	-2.37%	20.96%	-285.61%	63.03%	46.18%	-168.82%
EBIT Growth	-259.85%	159.28%	34.11%	247.89%	-16.69%	-125.44%	-368.93%	-1,479.47%	32.15%	13.64%	-24.98%
NOPAT Growth	-302.51%	138.24%	34.66%	241.21%	312.14%	-134.29%	-748.73%	-32.73%	31.65%	14.51%	-25.81%
Net Income Growth	-323.94%	-142.29%	93.55%	766.67%	203.26%	-47.89%	-300.07%	-1,628.17%	39.02%	10.51%	-37.22%
EPS Growth	-300.00%	-900.00%	65.00%	150.00%	14.29%	0.00%	0.00%	0.00%	39.66%	11.43%	-35.48%
Operating Cash Flow Growth	-32.35%	235.95%	-16.02%	148.30%	-47.82%	-93.75%	-1,930.34%	-146.95%	97.04%	459.60%	-25.53%
Free Cash Flow Firm Growth	-4,139.80%	102.88%	-303.13%	-654.76%	112.42%	-923.80%	-483.38%	88.05%	44.48%	-26.82%	23.41%
Invested Capital Growth	712.77%	-2.04%	6.04%	40.20%	3.50%	24.44%	109.72%	-2.67%	-2.81%	-0.74%	-3.58%
Revenue Q/Q Growth	2.34%	9.93%	5.82%	5.75%	8.03%	4.50%	-0.05%	2.61%	2.93%	2.55%	2.56%
EBITDA Q/Q Growth	-54.19%	46.37%	16.33%	-1.34%	3.87%	58.75%	-51.78%	16.84%	20.66%	-3.31%	6.84%
EBIT Q/Q Growth	-503.89%	632.99%	169.50%	-7.60%	-0.61%	83.06%	-121.83%	9.26%	6.90%	-0.41%	4.54%
NOPAT Q/Q Growth	-2,354.36%	632.99%	169.79%	-55.94%	167.80%	18.70%	12.81%	8.79%	6.76%	0.19%	4.13%
Net Income Q/Q Growth	-776.00%	-350.95%	96.58%	-61.39%	288.08%	184.30%	-117.09%	11.68%	8.68%	-1.28%	4.80%
EPS Q/Q Growth	-500.00%	-66.67%	61.11%	-22.22%	300.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	21.59%	-9.91%	49.85%	27.62%	-34.10%	225.21%	-2,677.86%	19.60%	91.66%	-53.20%	-61.79%
Free Cash Flow Firm Q/Q Growth	-5,078.49%	103.03%	0.00%	-979.07%	112.56%	2.60%	3.75%	18.63%	25.01%	-32.33%	-8.39%
Invested Capital Q/Q Growth	656.22%	-0.10%	1.60%	41.02%	3.31%	2.48%	-0.08%	-0.79%	-1.67%	-0.39%	0.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	43.84%	42.32%	42.44%	45.99%	48.15%	41.83%	38.62%	36.86%	41.34%	43.92%	43.21%
EBITDA Margin	3.51%	12.45%	10.79%	11.68%	9.55%	8.58%	9.52%	-16.79%	-5.35%	-2.58%	-6.29%
Operating Margin	-5.65%	0.93%	1.21%	3.63%	3.18%	-3.15%	-24.52%	-30.92%	-18.21%	-13.94%	-15.93%
EBIT Margin	-3.64%	0.93%	1.20%	3.63%	2.05%	-0.48%	-2.06%	-30.96%	-18.10%	-14.00%	-15.89%
Profit (Net Income) Margin	-2.54%	-2.65%	-0.16%	0.95%	1.96%	0.94%	-1.72%	-28.30%	-14.87%	-11.92%	-14.85%
Tax Burden Percent	56.47%	78.31%	14.94%	69.04%	219.64%	-29.68%	55.37%	90.53%	90.60%	97.58%	97.97%
Interest Burden Percent	123.49%	-363.94%	-91.70%	38.03%	43.52%	659.60%	150.86%	100.95%	90.67%	87.23%	95.40%
Effective Tax Rate	0.00%	0.00%	0.00%	30.96%	-119.64%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-2.46%	0.53%	0.70%	1.94%	6.74%	-2.02%	-10.00%	-9.94%	-6.98%	-6.08%	-7.82%
ROIC Less NNEP Spread (ROIC-NNEP)	9.94%	-10.27%	-1.90%	-2.60%	-198.82%	-13.97%	-116.38%	-69.21%	-18.38%	-16.36%	-23.81%
Return on Net Nonoperating Assets (RNNOA)	0.76%	-3.43%	-0.91%	-0.94%	-4.80%	2.72%	9.08%	-3.76%	-2.09%	-2.46%	-4.61%
Return on Equity (ROE)	-1.70%	-2.89%	-0.20%	1.01%	1.93%	0.69%	-0.93%	-13.70%	-9.07%	-8.54%	-12.42%
Cash Return on Invested Capital (CROIC)	-158.63%	2.59%	-5.16%	-31.53%	3.30%	-23.80%	-80.86%	-7.23%	-4.13%	-5.33%	-4.17%
Operating Return on Assets (OROA)	-1.68%	0.63%	0.85%	2.37%	1.38%	-0.25%	-0.70%	-8.74%	-6.26%	-5.57%	-7.71%
Return on Assets (ROA)	-1.17%	-1.78%	-0.12%	0.62%	1.32%	0.49%	-0.58%	-7.99%	-5.14%	-4.74%	-7.21%
Return on Common Equity (ROCE)	-1.54%	-2.54%	-0.17%	0.94%	1.93%	0.69%	-0.93%	-13.70%	-9.07%	-8.54%	-12.42%
Return on Equity Simple (ROE_SIMPLE)	-1.21%	-3.75%	-0.23%	0.82%	1.58%	0.60%	-0.75%	-14.45%	-9.34%	-8.72%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.94	1.51	2.03	6.93	29	-9.79	-83	-110	-75	-64	-81
NOPAT Margin	-3.95%	0.65%	0.85%	2.50%	6.99%	-2.20%	-17.16%	-21.65%	-12.75%	-9.76%	-11.15%
Net Nonoperating Expense Percent (NNEP)	-12.39%	10.81%	2.61%	4.55%	205.56%	11.94%	106.37%	59.28%	11.39%	10.28%	15.99%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-7.20%	-5.10%	-4.47%	-6.88%
Cost of Revenue to Revenue	56.16%	57.68%	57.56%	54.01%	51.85%	58.17%	61.38%	63.14%	58.66%	56.08%	56.79%
SG&A Expenses to Revenue	33.70%	27.58%	29.29%	30.65%	31.31%	32.35%	45.70%	47.74%	41.09%	39.32%	37.58%
R&D to Revenue	4.21%	2.01%	1.51%	1.08%	2.08%	1.85%	4.52%	5.95%	4.62%	4.72%	5.10%
Operating Expenses to Revenue	49.49%	41.39%	41.23%	42.36%	44.96%	44.97%	63.14%	67.79%	59.55%	57.86%	59.14%
Earnings before Interest and Taxes (EBIT)	-3.64	2.16	2.89	10	8.38	-2.13	-9.99	-158	-107	-92	-116
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3.51	29	26	32	39	38	46	-86	-32	-17	-46
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.27	4.11	4.14	3.66	6.02	8.61	3.79	1.17	2.19	2.34	1.82
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	16.76	16.49	30.26	17.42	45.19	53.03	59.23
Price to Revenue (P/Rev)	4.76	2.90	2.97	4.24	7.47	13.45	8.67	2.29	3.49	3.20	2.09
Price to Earnings (P/E)	0.00	0.00	0.00	192.66	381.45	1,432.85	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.52%	0.26%	0.07%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.93	2.82	2.82	3.05	6.91	10.85	3.92	1.15	2.05	2.15	1.67
Enterprise Value to Revenue (EV/Rev)	5.53	3.41	3.49	4.59	7.28	13.10	9.12	2.48	3.69	3.44	2.34
Enterprise Value to EBITDA (EV/EBITDA)	157.26	27.35	32.32	39.26	76.28	152.71	95.80	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	366.30	289.84	126.23	355.51	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	523.28	412.35	183.10	104.24	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	86.27	36.75	46.44	28.34	127.42	3,986.40	0.00	0.00	0.00	323.17	325.78
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	107.55	0.00	0.00	212.99	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.30	0.57	0.52	0.33	0.19	0.24	0.48	0.54	0.57	0.60	0.41
Long-Term Debt to Equity	0.24	0.52	0.47	0.31	0.18	0.24	0.48	0.54	0.57	0.38	0.41
Financial Leverage	0.08	0.33	0.48	0.36	0.02	-0.19	-0.08	0.05	0.11	0.15	0.19
Leverage Ratio	1.45	1.62	1.74	1.62	1.47	1.41	1.59	1.71	1.76	1.80	1.72
Compound Leverage Factor	1.79	-5.90	-1.60	0.62	0.64	9.32	2.39	1.73	1.60	1.57	1.64
Debt to Total Capital	23.06%	36.26%	34.01%	24.86%	16.03%	19.49%	32.45%	34.91%	36.37%	37.49%	29.01%
Short-Term Debt to Total Capital	4.52%	2.98%	2.90%	1.85%	0.83%	0.00%	0.00%	0.00%	0.00%	13.91%	0.00%
Long-Term Debt to Total Capital	18.54%	33.28%	31.11%	23.01%	15.20%	19.49%	32.45%	34.91%	36.37%	23.58%	29.01%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	9.24%	7.81%	10.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	67.70%	55.92%	55.47%	75.14%	83.98%	80.51%	67.55%	65.09%	63.63%	62.51%	70.99%
Debt to EBITDA	20.35	3.68	4.07	3.28	2.48	4.41	11.55	-6.26	-17.01	-31.79	-7.47
Net Debt to EBITDA	13.68	3.24	3.57	2.98	-1.95	-4.14	4.68	-1.14	-3.89	-9.06	-3.98
Long-Term Debt to EBITDA	16.36	3.38	3.72	3.04	2.35	4.41	11.55	-6.26	-17.01	-19.99	-7.47
Debt to NOPAT	-18.10	70.38	51.90	15.29	3.39	-17.16	-6.41	-4.85	-7.14	-8.39	-4.21
Net Debt to NOPAT	-12.16	62.08	45.59	13.88	-2.67	16.10	-2.59	-0.88	-1.63	-2.39	-2.25
Long-Term Debt to NOPAT	-14.55	64.59	47.47	14.16	3.21	-17.16	-6.41	-4.85	-7.14	-5.28	-4.21
Altman Z-Score	2.82	3.32	3.72	4.47	10.04	13.09	3.92	1.16	1.97	1.88	1.81
Noncontrolling Interest Sharing Ratio	9.58%	12.12%	14.19%	6.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.06	2.07	2.35	1.70	4.55	6.13	7.81	6.73	6.20	1.98	4.26
Quick Ratio	1.81	1.79	2.01	1.42	4.18	5.51	4.92	6.20	5.67	1.78	3.61
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-255	7.34	-15	-113	14	-115	-672	-80	-45	-57	-43
Operating Cash Flow to CapEx	288.62%	284.99%	131.75%	312.97%	116.68%	5.02%	-41.66%	-351.16%	-6.79%	17.10%	19.36%
Free Cash Flow to Firm to Interest Expense	-298.38	0.73	-2.69	-18.06	2.96	-9.66	-81.74	-10.60	-6.46	-8.55	-11.54
Operating Cash Flow to Interest Expense	7.49	2.15	3.26	7.19	4.94	0.12	-3.25	-8.71	-0.28	1.06	1.39
Operating Cash Flow Less CapEx to Interest Expense	4.89	1.39	0.78	4.89	0.71	-2.32	-11.05	-11.18	-4.45	-5.14	-5.80
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.46	0.67	0.71	0.65	0.67	0.52	0.34	0.28	0.35	0.40	0.49
Accounts Receivable Turnover	2.88	4.44	4.14	4.03	4.78	4.42	4.42	4.40	4.72	4.69	4.70
Inventory Turnover	14.51	23.54	20.15	18.54	18.39	11.77	11.23	13.50	14.33	14.56	14.93
Fixed Asset Turnover	4.02	6.76	6.81	5.68	6.54	5.92	4.96	4.81	6.08	7.10	8.13
Accounts Payable Turnover	5.98	9.14	10.16	10.59	11.35	11.61	13.86	16.75	16.99	17.67	18.48
Days Sales Outstanding (DSO)	126.94	82.24	88.07	90.57	76.41	82.57	82.51	83.01	77.41	77.85	77.73
Days Inventory Outstanding (DIO)	25.15	15.51	18.11	19.69	19.85	31.01	32.49	27.03	25.47	25.08	24.44
Days Payable Outstanding (DPO)	61.08	39.92	35.94	34.47	32.15	31.43	26.33	21.79	21.48	20.66	19.75
Cash Conversion Cycle (CCC)	91.01	57.82	70.25	75.80	64.10	82.14	88.67	88.25	81.40	82.26	82.42
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	286	280	297	417	431	537	1,125	1,095	1,065	1,057	1,019
Invested Capital Turnover	0.62	0.82	0.83	0.78	0.96	0.92	0.58	0.46	0.55	0.62	0.70
Increase / (Decrease) in Invested Capital	251	-5.83	17	119	15	105	589	-30	-31	-7.93	-38
Enterprise Value (EV)	552	789	838	1,269	2,978	5,820	4,417	1,264	2,185	2,270	1,704
Market Capitalization	475	673	712	1,173	3,054	5,978	4,201	1,167	2,062	2,115	1,522
Book Value per Share	$3.47	$2.09	$2.14	$3.45	$4.86	$6.25	$9.00	$7.90	$7.39	$7.03	$6.47
Tangible Book Value per Share	($0.41)	($0.77)	($0.61)	($0.19)	$1.74	$3.27	$1.13	$0.53	$0.36	$0.31	$0.20
Total Capital	309	293	310	426	604	862	1,641	1,533	1,480	1,443	1,178
Total Debt	71	106	105	106	97	168	532	535	538	541	342
Total Long-Term Debt	57	97	96	98	92	168	532	535	538	340	342
Net Debt	48	94	93	96	-76	-158	216	97	123	154	182
Capital Expenditures (CapEx)	2.22	7.54	14	14	20	29	64	19	29	41	27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	33	37	46	41	59	79	277	77	85	109	128
Debt-free Net Working Capital (DFNWC)	56	49	58	51	232	376	594	515	501	496	288
Net Working Capital (NWC)	42	41	49	43	227	376	594	515	501	295	288
Net Nonoperating Expense (NNE)	-1.41	7.65	2.43	4.29	21	-14	-75	34	13	14	27
Net Nonoperating Obligations (NNO)	48	94	93	96	-76	-158	17	97	123	154	182
Total Depreciation and Amortization (D&A)	7.14	27	23	22	31	40	56	72	75	75	70
Debt-free, Cash-free Net Working Capital to Revenue	32.95%	15.93%	18.97%	14.74%	14.39%	17.84%	57.29%	15.18%	14.42%	16.46%	17.65%
Debt-free Net Working Capital to Revenue	56.42%	21.33%	24.31%	18.29%	56.71%	84.50%	122.70%	101.10%	84.60%	75.02%	39.59%
Net Working Capital to Revenue	42.39%	17.56%	20.56%	15.45%	55.48%	84.50%	122.70%	101.10%	84.60%	44.63%	39.59%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.39)	$0.00	$0.07	$0.08	$0.04	($0.07)	$0.00	$0.00	($0.62)	($0.84)
Adjusted Weighted Average Basic Shares Outstanding	0.00	77.54M	79.43M	85.62M	100.47M	108.58M	119.96M	124.22M	125.50M	126.66M	128.10M
Adjusted Diluted Earnings per Share	$0.00	($0.39)	$0.00	$0.07	$0.08	$0.04	($0.07)	$0.00	$0.00	($0.62)	($0.84)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	77.54M	79.43M	91.57M	103.62M	111.79M	119.96M	124.22M	125.50M	126.66M	128.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	78.82M	80.51M	94.57M	104.83M	116.94M	124.03M	127.46M	127.61M	128.46M	129.81M
Normalized Net Operating Profit after Tax (NOPAT)	-3.94	3.93	2.03	6.93	9.10	-9.79	-83	-107	-68	-60	-62
Normalized NOPAT Margin	-3.95%	1.70%	0.85%	2.50%	2.23%	-2.20%	-17.16%	-21.03%	-11.43%	-9.05%	-8.48%
Pre Tax Income Margin	-4.50%	-3.38%	-1.10%	1.38%	0.89%	-3.16%	-3.11%	-31.26%	-16.41%	-12.21%	-15.16%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.26	0.22	0.52	1.61	1.77	-0.18	-1.22	-20.82	-15.50	-13.98	-30.80
NOPAT to Interest Expense	-4.62	0.15	0.37	1.11	6.04	-0.82	-10.11	-14.55	-10.92	-9.74	-21.61
EBIT Less CapEx to Interest Expense	-6.85	-0.54	-1.95	-0.68	-2.46	-2.62	-9.02	-23.30	-19.67	-20.18	-37.99
NOPAT Less CapEx to Interest Expense	-7.21	-0.60	-2.10	-1.18	1.80	-3.26	-17.92	-17.03	-15.08	-15.95	-28.81
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	129,812,211.00	130,211,780.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	129,812,211.00	130,211,780.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-0.13	0.02
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	12.15%	13.86%	11.97%	10.44%	10.57%	7.55%	10.23%	11.90%	10.56%	11.09%	11.21%
EBITDA Growth	108.32%	28.86%	69.48%	60.18%	-86.10%	21.46%	-845.13%	-386.42%	3,818.18%	81.66%	104.17%
EBIT Growth	30.07%	12.38%	24.76%	14.04%	-2.07%	9.96%	-114.86%	-30.98%	29.22%	34.25%	79.24%
NOPAT Growth	29.60%	12.85%	26.60%	12.39%	0.93%	8.97%	-117.07%	-27.44%	27.10%	34.44%	64.08%
Net Income Growth	36.85%	12.13%	23.38%	4.41%	-6.97%	4.21%	-141.88%	-53.28%	35.52%	34.01%	104.96%
EPS Growth	0.00%	16.00%	0.00%	6.67%	0.00%	4.76%	0.00%	-50.00%	0.00%	35.00%	105.71%
Operating Cash Flow Growth	582.61%	-104.18%	997.42%	268.20%	-44.89%	2.27%	46.34%	-3.92%	-86.30%	67.87%	-1.82%
Free Cash Flow Firm Growth	54.36%	-165.60%	-91.88%	56.74%	-127.81%	-121.80%	331.99%	266.46%	673.38%	345.62%	125.87%
Invested Capital Growth	-2.81%	-1.38%	-1.47%	-2.02%	-0.74%	-0.51%	-3.35%	-4.21%	-3.58%	-4.40%	-1.69%
Revenue Q/Q Growth	2.37%	0.44%	5.29%	2.02%	2.49%	-2.31%	7.91%	3.57%	1.26%	-1.84%	8.03%
EBITDA Q/Q Growth	111.64%	-1,970.14%	73.74%	30.36%	104.06%	-10,664.77%	-216.06%	64.16%	132.74%	-153.36%	180.33%
EBIT Q/Q Growth	24.05%	-67.10%	28.83%	4.84%	9.81%	-47.41%	-69.83%	41.99%	51.26%	-36.93%	46.38%
NOPAT Q/Q Growth	23.23%	-64.57%	28.22%	3.39%	13.19%	-51.21%	-71.17%	43.28%	50.34%	-35.98%	6.21%
Net Income Q/Q Growth	22.63%	-88.89%	31.11%	5.06%	13.42%	-69.17%	-73.95%	39.84%	63.58%	-73.12%	113.08%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	115.38%
Operating Cash Flow Q/Q Growth	423.52%	-245.72%	153.61%	-33.44%	5.99%	-358.44%	180.27%	-56.30%	-84.88%	-705.88%	345.29%
Free Cash Flow Firm Q/Q Growth	297.68%	-135.44%	108.92%	1,146.96%	-170.55%	-182.67%	117.37%	957.79%	10.39%	21.09%	-84.03%
Invested Capital Q/Q Growth	-1.67%	1.22%	-0.91%	-0.65%	-0.39%	1.46%	-3.74%	-1.53%	0.26%	0.59%	-1.02%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	43.45%	41.90%	44.07%	44.62%	44.92%	43.59%	42.61%	42.84%	43.83%	43.32%	45.56%
EBITDA Margin	0.41%	-7.58%	-1.89%	-1.29%	0.05%	-5.53%	-16.20%	-5.61%	1.81%	-0.99%	0.73%
Operating Margin	-11.94%	-19.56%	-13.34%	-12.63%	-10.70%	-16.56%	-26.27%	-14.38%	-7.05%	-9.77%	-4.85%
EBIT Margin	-11.86%	-19.73%	-13.34%	-12.44%	-10.95%	-16.52%	-26.00%	-14.56%	-7.01%	-9.78%	-4.85%
Profit (Net Income) Margin	-9.21%	-17.32%	-11.33%	-10.55%	-8.91%	-15.43%	-24.87%	-14.45%	-5.20%	-9.16%	1.11%
Tax Burden Percent	93.72%	97.76%	98.03%	99.16%	95.01%	101.04%	98.42%	102.80%	79.65%	97.31%	122.56%
Interest Burden Percent	82.85%	89.79%	86.67%	85.48%	85.64%	92.42%	97.18%	96.49%	93.07%	96.30%	-18.66%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-22.56%
Return on Invested Capital (ROIC)	-4.58%	-7.71%	-5.45%	-5.31%	-4.66%	-7.25%	-12.07%	-6.88%	-3.46%	-4.87%	-4.45%
ROIC Less NNEP Spread (ROIC-NNEP)	-5.78%	-11.87%	-7.81%	-7.30%	-6.43%	-11.07%	-19.20%	-11.85%	-3.75%	-7.15%	2.54%
Return on Net Nonoperating Assets (RNNOA)	-0.66%	-1.70%	-1.16%	-1.13%	-0.97%	-2.06%	-3.58%	-2.24%	-0.73%	-1.58%	0.63%
Return on Equity (ROE)	-5.24%	-9.41%	-6.62%	-6.45%	-5.63%	-9.32%	-15.65%	-9.12%	-4.19%	-6.45%	-3.82%
Cash Return on Invested Capital (CROIC)	-4.13%	-5.27%	-4.72%	-3.99%	-5.33%	-5.31%	-4.26%	-3.85%	-4.17%	-2.60%	-2.97%
Operating Return on Assets (OROA)	-4.10%	-7.20%	-5.02%	-4.83%	-4.36%	-6.85%	-11.80%	-6.85%	-3.40%	-4.95%	-2.71%
Return on Assets (ROA)	-3.19%	-6.32%	-4.27%	-4.09%	-3.55%	-6.40%	-11.29%	-6.79%	-2.52%	-4.64%	0.62%
Return on Common Equity (ROCE)	-5.24%	-9.41%	-6.62%	-6.45%	-5.63%	-9.32%	-15.65%	-9.12%	-4.19%	-6.45%	-3.82%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-9.12%	-8.58%	-8.56%	0.00%	-8.73%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	-21	-15	-15	-13	-19	-33	-19	-9.39	-13	-12
NOPAT Margin	-8.36%	-13.69%	-9.34%	-8.84%	-7.49%	-11.59%	-18.39%	-10.07%	-4.94%	-6.84%	-5.94%
Net Nonoperating Expense Percent (NNEP)	1.20%	4.16%	2.35%	1.99%	1.76%	3.82%	7.13%	4.98%	0.29%	2.28%	-6.99%
Return On Investment Capital (ROIC_SIMPLE)	-0.88%	-	-	-	-0.89%	-1.36%	-2.79%	-1.60%	-0.80%	-1.09%	-1.03%
Cost of Revenue to Revenue	56.55%	58.10%	55.93%	55.38%	55.08%	56.41%	57.39%	57.16%	56.17%	56.68%	54.44%
SG&A Expenses to Revenue	38.42%	42.11%	38.50%	39.90%	37.00%	40.59%	39.57%	37.21%	33.40%	35.22%	31.55%
R&D to Revenue	4.58%	4.88%	4.79%	4.58%	4.63%	6.06%	4.98%	4.63%	4.83%	5.11%	5.34%
Operating Expenses to Revenue	55.39%	61.47%	57.41%	57.25%	55.62%	60.15%	68.87%	57.22%	50.88%	53.09%	50.41%
Earnings before Interest and Taxes (EBIT)	-18	-31	-22	-21	-19	-28	-47	-27	-13	-18	-9.79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.63	-12	-3.11	-2.17	0.09	-9.30	-29	-11	3.45	-1.84	1.48
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.19	2.17	1.93	2.08	2.34	1.37	1.10	1.19	1.82	1.16	2.42
Price to Tangible Book Value (P/TBV)	45.19	55.85	48.25	50.54	53.03	35.66	33.48	50.41	59.23	37.23	0.00
Price to Revenue (P/Rev)	3.49	3.28	2.82	2.93	3.20	1.81	1.37	1.41	2.09	1.29	2.48
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.05	2.00	1.80	1.93	2.15	1.31	1.08	1.16	1.67	1.13	2.10
Enterprise Value to Revenue (EV/Rev)	3.69	3.53	3.06	3.17	3.44	2.09	1.62	1.66	2.34	1.55	2.78
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	7,284.70	136.13	323.17	184.32	79.59	85.82	325.78	51.71	96.53
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.57	0.58	0.59	0.60	0.60	0.61	0.40	0.41	0.41	0.41	0.48
Long-Term Debt to Equity	0.57	0.58	0.37	0.37	0.38	0.38	0.40	0.41	0.41	0.41	0.48
Financial Leverage	0.11	0.14	0.15	0.16	0.15	0.19	0.19	0.19	0.19	0.22	0.25
Leverage Ratio	1.76	1.76	1.78	1.79	1.80	1.79	1.72	1.73	1.72	1.72	1.67
Compound Leverage Factor	1.46	1.58	1.55	1.53	1.54	1.65	1.67	1.67	1.60	1.65	-0.31
Debt to Total Capital	36.37%	36.85%	37.08%	37.30%	37.49%	37.89%	28.54%	28.94%	29.01%	29.23%	32.26%
Short-Term Debt to Total Capital	0.00%	0.00%	13.75%	13.84%	13.91%	14.06%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	36.37%	36.85%	23.33%	23.47%	23.58%	23.82%	28.54%	28.94%	29.01%	29.23%	32.26%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	63.63%	63.15%	62.92%	62.70%	62.51%	62.11%	71.46%	71.06%	70.99%	70.77%	67.74%
Debt to EBITDA	-17.01	-20.09	-27.32	-32.79	-31.79	-37.41	-8.37	-6.95	-7.47	-9.11	-544.75
Net Debt to EBITDA	-3.89	-5.74	-7.69	-9.26	-9.06	-12.69	-4.35	-3.61	-3.98	-5.22	-332.90
Long-Term Debt to EBITDA	-17.01	-20.09	-17.19	-20.63	-19.99	-23.53	-8.37	-6.95	-7.47	-9.11	-544.75
Debt to NOPAT	-7.14	-7.46	-8.09	-8.37	-8.39	-8.66	-4.24	-4.04	-4.21	-4.60	-7.81
Net Debt to NOPAT	-1.63	-2.13	-2.28	-2.36	-2.39	-2.94	-2.20	-2.10	-2.25	-2.64	-4.77
Long-Term Debt to NOPAT	-7.14	-7.46	-5.09	-5.26	-5.28	-5.45	-4.24	-4.04	-4.21	-4.60	-7.81
Altman Z-Score	2.14	2.12	1.76	1.85	2.03	1.30	1.28	1.38	2.05	1.41	2.33
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.20	7.48	2.01	1.99	1.98	2.05	3.92	3.91	4.26	4.42	3.60
Quick Ratio	5.67	6.85	1.84	1.82	1.78	1.82	3.16	3.26	3.61	3.71	3.03
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	18	-6.32	0.56	7.02	-4.96	-14	2.43	26	28	34	5.50
Operating Cash Flow to CapEx	252.01%	-464.01%	106.22%	85.62%	84.49%	-562.82%	321.52%	106.86%	17.06%	-162.74%	242.84%
Free Cash Flow to Firm to Interest Expense	10.60	-3.75	0.34	4.28	-3.05	-8.66	2.61	42.69	47.44	57.54	0.00
Operating Cash Flow to Interest Expense	10.58	-15.38	8.34	5.63	6.03	-15.65	21.79	14.73	2.24	-13.61	0.00
Operating Cash Flow Less CapEx to Interest Expense	6.38	-18.69	0.49	-0.95	-1.11	-18.43	15.01	0.95	-10.90	-21.97	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.35	0.36	0.38	0.39	0.40	0.41	0.45	0.47	0.49	0.51	0.56
Accounts Receivable Turnover	4.72	4.71	4.62	4.54	4.69	4.61	4.60	4.62	4.70	4.68	4.67
Inventory Turnover	14.33	15.88	14.97	14.99	14.56	14.95	13.47	15.15	14.93	14.23	14.02
Fixed Asset Turnover	6.08	6.40	6.54	6.87	7.10	7.58	7.76	7.95	8.13	8.61	9.21
Accounts Payable Turnover	16.99	17.32	20.54	21.82	17.67	21.68	17.30	20.50	18.48	20.14	17.74
Days Sales Outstanding (DSO)	77.41	77.44	79.02	80.49	77.85	79.12	79.36	78.93	77.73	77.95	78.24
Days Inventory Outstanding (DIO)	25.47	22.98	24.39	24.34	25.08	24.41	27.09	24.09	24.44	25.65	26.03
Days Payable Outstanding (DPO)	21.48	21.08	17.77	16.73	20.66	16.84	21.09	17.81	19.75	18.12	20.57
Cash Conversion Cycle (CCC)	81.40	79.34	85.63	88.10	82.26	86.69	85.36	85.21	82.42	85.48	83.70
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,065	1,078	1,068	1,061	1,057	1,072	1,032	1,016	1,019	1,025	1,014
Invested Capital Turnover	0.55	0.56	0.58	0.60	0.62	0.63	0.66	0.68	0.70	0.71	0.75
Increase / (Decrease) in Invested Capital	-31	-15	-16	-22	-7.93	-5.47	-36	-45	-38	-47	-17
Enterprise Value (EV)	2,185	2,158	1,923	2,043	2,270	1,403	1,118	1,175	1,704	1,159	2,128
Market Capitalization	2,062	2,004	1,771	1,890	2,115	1,219	941	997	1,522	963	1,900
Book Value per Share	$7.39	$7.32	$7.17	$7.09	$7.03	$6.91	$6.64	$6.49	$6.47	$6.38	$6.03
Tangible Book Value per Share	$0.36	$0.28	$0.29	$0.29	$0.31	$0.27	$0.22	$0.15	$0.20	$0.20	($0.07)
Total Capital	1,480	1,462	1,456	1,449	1,443	1,430	1,195	1,180	1,178	1,171	1,160
Total Debt	538	539	540	540	541	542	341	341	342	342	374
Total Long-Term Debt	538	539	340	340	340	341	341	341	342	342	374
Net Debt	123	154	152	153	154	184	177	177	182	196	229
Capital Expenditures (CapEx)	7.06	5.59	13	11	12	4.50	6.32	8.31	7.87	5.00	8.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	85	112	106	106	109	137	129	120	128	143	130
Debt-free Net Working Capital (DFNWC)	501	497	494	494	496	495	292	285	288	289	276
Net Working Capital (NWC)	501	497	294	294	295	294	292	285	288	289	276
Net Nonoperating Expense (NNE)	1.32	5.66	3.28	2.86	2.44	6.45	12	8.22	0.49	4.34	-14
Net Nonoperating Obligations (NNO)	123	154	152	153	154	184	178	178	182	196	229
Total Depreciation and Amortization (D&A)	19	19	19	19	19	18	18	17	17	16	11
Debt-free, Cash-free Net Working Capital to Revenue	14.42%	18.40%	16.95%	16.53%	16.46%	20.42%	18.68%	16.99%	17.65%	19.16%	16.97%
Debt-free Net Working Capital to Revenue	84.60%	81.42%	78.68%	76.73%	75.02%	73.68%	42.43%	40.13%	39.59%	38.75%	35.96%
Net Working Capital to Revenue	84.60%	81.42%	46.84%	45.62%	44.63%	43.76%	42.43%	40.13%	39.59%	38.75%	35.96%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.21)	$0.00	($0.14)	$0.00	($0.20)	$0.00	($0.21)	$0.00	($0.13)	$0.02
Adjusted Weighted Average Basic Shares Outstanding	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.42M	128.10M	129.17M	129.63M
Adjusted Diluted Earnings per Share	$0.00	($0.21)	$0.00	($0.14)	$0.00	($0.20)	$0.00	($0.21)	$0.00	($0.13)	$0.02
Adjusted Weighted Average Diluted Shares Outstanding	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M	128.42M	128.10M	129.17M	130.83M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	127.61M	127.71M	128.16M	128.36M	128.46M	128.69M	129.18M	129.39M	129.81M	130.21M	128.48M
Normalized Net Operating Profit after Tax (NOPAT)	-12	-20	-14	-14	-12	-19	-19	-14	-9.39	-13	-6.84
Normalized NOPAT Margin	-7.82%	-12.62%	-8.68%	-8.42%	-6.79%	-11.59%	-10.65%	-7.43%	-4.94%	-6.84%	-3.39%
Pre Tax Income Margin	-9.83%	-17.72%	-11.56%	-10.64%	-9.38%	-15.27%	-25.27%	-14.05%	-6.52%	-9.42%	0.91%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-10.98	-18.30	-13.17	-12.72	-11.60	-17.16	-50.53	-45.35	-22.25	-30.52	0.00
NOPAT to Interest Expense	-7.73	-12.70	-9.22	-9.04	-7.93	-12.04	-35.73	-31.36	-15.68	-21.35	0.00
EBIT Less CapEx to Interest Expense	-15.17	-21.61	-21.02	-19.29	-18.74	-19.94	-57.31	-59.14	-35.39	-38.88	0.00
NOPAT Less CapEx to Interest Expense	-11.93	-16.01	-17.07	-15.61	-15.07	-14.82	-42.51	-45.15	-28.82	-29.71	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

NeoGenomics (NASDAQ: NEO) is still growing revenue, but profitability and cash generation remain inconsistent. Over the last several years, the company has shown steady top-line expansion and a stronger balance sheet than many loss-making small-cap healthcare names, but operating losses, heavy non-cash charges, and sizable debt continue to weigh on the story.

What stands out most from the latest quarter:

Q1 2026 revenue rose to $186.7 million, up from $168.0 million in Q1 2025 and $156.2 million in Q1 2024, showing continued demand growth.
Gross profit improved to $80.9 million in Q1 2026, with gross margin around 43%, slightly better than recent comparable periods.
The company ended Q1 2026 with $146.1 million in cash and equivalents, providing liquidity despite recent losses.
Total equity remained strong at $828.8 million, which helps support the balance sheet.
Revenue has trended upward over the multi-year period, rising from about $137.2 million in Q1 2023 to nearly $186.7 million in Q1 2026.
Depreciation and amortization remain large but also cushion reported losses in cash flow, meaning the business still generates meaningful non-cash earnings add-backs.
Long-term debt has been relatively stable around the $340 million to $342 million range in recent quarters.
The company has maintained substantial goodwill and intangible assets, reflecting its acquisition history and the importance of future operating performance to justify those assets.
Q1 2026 operating income was a loss of $18.2 million, and net loss was $17.1 million, so the business is still not profitable at the operating level.
Operating cash flow was negative $8.1 million in Q1 2026, after being positive in several prior quarters, suggesting working-capital pressure.
The company burned $13.5 million in total cash during Q1 2026.
Shares outstanding continue to creep higher over time, which can dilute per-share progress for investors.

Revenue trend: NeoGenomics has posted a fairly consistent upward sales trend over the past four years. Quarterly revenue moved from roughly $137 million in Q1 2023, to $156 million in Q1 2024, $168 million in Q1 2025, and $187 million in Q1 2026. That is a constructive sign and suggests the business is still gaining scale.

Profitability remains the key issue. Even with higher revenue, operating expenses have stayed elevated. In Q1 2026, SG&A, marketing, and R&D totaled more than $99 million, which was enough to push operating income to a loss despite healthy gross profit. The same pattern has appeared throughout the historical periods provided: NeoGenomics is making progress on sales, but not yet converting that growth into consistent operating leverage.

Cash flow has been volatile. Some earlier quarters, such as Q2 2025 and Q4 2024, generated positive operating cash flow, but Q1 2026 swung back to a negative result. That matters because investors typically want to see earnings losses narrowing and operating cash flow stabilizing. Right now, NeoGenomics has not yet established that consistency.

The balance sheet is a mixed picture. On the positive side, the company still has a sizable cash cushion. On the other hand, total liabilities were $517.8 million in Q1 2026, including $342.2 million of long-term debt. The company also carries a large amount of goodwill and intangible assets, which can be a risk if future performance disappoints.

Bottom line: NeoGenomics looks like a company with a solid revenue growth profile and enough liquidity to keep operating, but it is still working through margin pressure, recurring losses, and uneven cash generation. For retail investors, the stock’s upside will likely depend on whether management can turn revenue growth into durable operating profit and positive free cash flow.

07/29/26 12:09 AM ETAI Generated. May Contain Errors.

NeoGenomics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, NeoGenomics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

NeoGenomics' net income appears to be on an upward trend, with a most recent value of -$108.03 million in 2025, rising from -$2.54 million in 2015. The previous period was -$78.73 million in 2024. Find out what analysts predict for NeoGenomics in the coming months.

NeoGenomics' total operating income in 2025 was -$115.88 million, based on the following breakdown:

Total Gross Profit: $314.29 million
Total Operating Expenses: $430.17 million

Over the last 10 years, NeoGenomics' total revenue changed from $99.80 million in 2015 to $727.33 million in 2025, a change of 628.8%.

NeoGenomics' total liabilities were at $523.27 million at the end of 2025, a 28.9% decrease from 2024, and a 362.4% increase since 2015.

In the past 10 years, NeoGenomics' cash and equivalents has ranged from $9.81 million in 2018 to $367.01 million in 2024, and is currently $159.62 million as of their latest financial filing in 2025.

Over the last 10 years, NeoGenomics' book value per share changed from 3.47 in 2015 to 6.47 in 2025, a change of 86.2%.

Related Companies

Financial statements for NASDAQ:NEO last updated on 7/28/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Financials

Financials Breakdown Chart

Key Financial Trends

NeoGenomics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeoGenomics (NEO) Financials

Annual Income Statements for NeoGenomics

Quarterly Income Statements for NeoGenomics

Annual Cash Flow Statements for NeoGenomics

Quarterly Cash Flow Statements for NeoGenomics

Annual Balance Sheets for NeoGenomics

Quarterly Balance Sheets for NeoGenomics

Annual Metrics And Ratios for NeoGenomics

Quarterly Metrics And Ratios for NeoGenomics

Financials Breakdown Chart

Key Financial Trends

NeoGenomics Financials - Frequently Asked Questions

When does NeoGenomics' financial year end?

How has NeoGenomics' net income changed over the last 10 years?

What is NeoGenomics' operating income?

How has NeoGenomics' revenue changed over the last 10 years?

How much debt does NeoGenomics have?

How much cash does NeoGenomics have?

How has NeoGenomics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools